Posts tagged GILD


J.P. Morgan Weighs in on Sangamo Therapeutics Inc’s (SGMO) Collaboration with Kite

Sangamo Therapeutics Inc (NASDAQ:SGMO) has just announced a strategic collaboration with Gilead Sciences, Inc’s (NASDAQ:GILD) company …

Gilead Sciences’ HIV Franchise Is Poised to Recapture Share, Says Senior Analyst Phil Nadeau

Gilead Sciences, Inc. (NASDAQ:GILD), which built its reputation on turning HIV drug cocktails into easy-to-use, daily, …

Gilead Sciences, Inc. Notches FDA Approval for Biktarvy in HIV-1

In a landmark advancement against the onslaught of AIDS, the FDA approved today a once-daily single tablet …

Sing Hallelujah! Gilead Sciences, Inc. Shares Are on the Move; Oppenheimer Weighs In

Oppenheimer’s Hartaj Singh notes that Gilead outperformed his 4Q expectations, but continues to play it safe on the giant.

Teva Pharmaceutical Launches First Generic Formulation of Gilead’s Blockbuster Antiretroviral Truvada

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced this morning the exclusive US launch of Viread®1 …

Jason Kolbert Is Confident Gilead Sciences, Inc. (GILD) Can Resolve Any Yescarta Patient Backlog Challenges

Though Yescarta launch has seen patients condemned to waiting lists, Maxim’s Jason Kolbert is “inspired” by GILD’s global plan to commercialize the drug.

Jason McCarthy’s Take on Gilead Sciences, Inc. (GILD) Following ASH Data

ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.

Gilead Sciences, Inc. Attracts a New Bull Thanks to “Gift” of Kite

Maxim’s McCarthy now sees 27% upside potential for Gilead, impressed with management’s plans for lymphoma asset Yescarta.